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1. Introduction 
The stimulatory effect of glucocorticoids and 
cyclic AMP (or glucagon) on the induction of hepatic 
tyrosine aminotransferase (EC 2.6.1.5) (TAT) has 
well been documented and its de novo synthesis was 
evidenced in rat liver [ 1,2] and in cultured cells [3]. 
Given together with glucocorticoids to animals or to 
cultured cells, cyclic AMP exerts a more than additive 
effect in the induction of TAT [2-41. Recent work 
of Krone et al. [5] suggests a role of the pharmacolo- 
gical dose of hydrocortisone in maintaining the 
induced level of TAT and phosphenolpyruvate car- 
boxykinase (GTP) (EC 4.1.1.32) brought about by 
I@, 02’-dibutyryl cyclic AMP (DBcAMP) in rat liver. 
Early works from our laboratory revealed that adminis- 
tration of a physiological dose of glucocorticoids is 
essential to the substrate- or L-tryptophan-mediated 
stimulation of TAT in the liver of adrenalectomized . 
rats [6-81. In contrast to TAT the DBcAMP-mediated 
induction of L-serine:pyruvate aminotransferase 
(EC 2.6.1.5 1) is inhibited by cortisone acetate at a 
dose which stimulates TAT in rat liver [9,10]. The 
present study demonstrates that a physiological dose 
of cortisone acetate restores the reduced response of 
the enzyme to the DBcAMP-mediated induction in 
adrenalectomized rats nearly to the level of intact 
animals. 
2. Materials and methods 
2.1. Animals and their treatments 
Female Wistar rats weighing 120- 150 g were main- 
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tained at 25°C under the controlled lighting (12 hr) 
and darkness (12 hr) on a laboratory chow (Altromin 
GmbH, Lage) and water ad libitum. Adrenalectomy 
was performed bilaterally under ether anesthesia and 
the animals were fed the chow and physiological 
saline as a drinking water usually for 6 to 8 days until 
the animals were killed. They were sacrificed between 
080° and 130° h in order to avoid the possible 
diurnal alteration in the enzyme activity [ 111. Gluc- 
gon (Serva Feinbiochemica), DBcAMP, actinomycin D 
(Boehringer Mannheim) were injected intraperitoneally. 
2.2. Preparation of enzyme extracts and the enzyme 
assay 
Rats were killed by decapitation and the livers 
were quickly removed, chilled over ice, weighed and 
homogenized in 5 ~01s. of ice cold 50 mM sodium 
pyrophosphate buffer (pH 7.6) containing 0.14 M 
KCl, 1 mM EDTA and 10 pM pyridoxal 5’-phosphate 
in a Ultra-Turrax homogenizer at 2000 rev/min for 
20 sec. The homogenate was centrifuged at 770 g for 
10 min and the resultant supernatant was further 
diluted with 3 vols of the homogenization buffer for 
the assay of tyrosine aminotransferase by the method 
of Rosen et al. [ 121. The units of enzyme activity 
were defined as pmoles of p-hydroxyphenylpyruvate 
formed per hr under the assay conditions. 
2.3. Plasma glucocorticoid determination 
Glucocorticoids in rat plasma were determined by 
the competitive protein-binding radioassay [ 131 
using Cortipac radioassay kit (Amersham Buchler 
GmbH & Co. KG). 
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3. Results 
Fig.1 illustrates the change in the inducibility of 
TAT by DBcAMP and plasma level of glucocorticoid 
following adrenalectomy of rats. Degree of induction 
by the cyclic AMP rapidly decreases following opera- 
tion with a half-time of about 40 min and reaches a 
constant level by 5 hr, at which time, however, 
DBcAMP is still able to induce the enzyme to an 
extent of 40% of the unoperated control level. The 
reduced postoperational response even persists for 
8 days without any decline. Plasma glucocorticoid 
level decreases more rapidly and pronounced; it 
reaches a minimal level within 60 min after operation. 
As shown in fig.2 the response of the enzyme to 
DBcAMP is considerably lower in adrenalectomized 
rats than in the intact animals at all dose levels of 
DBcAMP tested. Given cortisone acetate at a dose of 
0.2 mg/lOO g body weight simultaneously with nucleo- 
tide inducer, which alone does not influence the 
basal enzyme level (fig.2), the reduced inducibility 
appreciably restores at all dose levels of the inducer. 
In all these three groups of rats, however, the efficiency 
of DBcAMP, as estimated from the half-maximal dose 
of DBcAMP, was almost identical (2 mg/ 100 g body 
weight). These results clearly demonstrate a ‘potentia- 
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Fig.1. Change in the inducibility of TAT by DBcAMP following 
adrenalectomy. Rats at various times after adrenalectomy were 
injected with DBcAMP (3 mg/lOO g) and the enzyme in the 
liver was assayed 3 hr later. Data are mean f S.E. for 5 or 6 
rats. (o-o) induced by DBcAMP; (0) intact rats without 
DBcAMP; (A) rats at 8 days after operation, without DBcAMP; 
(X---X) plasma corticosterone level. 
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Fig.2. DBcAMP-dose depence of TAT induction in the liver 
of intact, adrenalectomized or cortisone-treated adrenalecto- 
mized rats. Intact rats, adrenalectomized rats at 8 days after 
operation and such animals received cortisone acetate (0.2 
mg/lOO g) were injected with varying dose levels of DBcAMP 
and the enzyme was assayed 3 hr later. Data are mean + S.E. 
for 5 or 6 rats. (0) intact; (0) adrenalectomized; (3) cortisone- 
treated adrenalectomized rats. 
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Fig.3. Change in the inducibility of TAT by DBcAMP following 
injection of cortisone acetate. Adrenalectomized rats at 
various times after cortisone acetate injection (0.2 mg/lOO g) 
received DBcAMP (3 mg/lOO g) and the enzyme was assayed 
2 hr later. Data are mean r SE. for 5 or 6 rats. (o-o) induced 
by DBcAMP after cortisone acetate; (0) induced by DBcAMP 
before cortisone acetate; (A) basal level without DBcAMP. 
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ting’ effect of cortisone acetate on the response of 
TAT to the DBcAMP-mediated induction. The 
response of the enzyme to glucagon can be equally 
potentiated by such a dose of cortisone acetate (data 
are not shown). Lower doses of cortisone acetate 
failed to show such an effect. The inducibility of the 
enzyme by DBcAMP was then followed at various 
times after cortisone injection into adrenalectomized 
rats (fig.3). The potentiating effect of cortisone ace- 
tate continues for at least 60 min and is no longer 
detectable 120 min after the glucocorticoid injection. 
Fig.4 represents the effect of such a dose of corti- 
sone acetate on the time course of DBcAMP-mediated 
TAT induction. Cortisone acetate, which alone does 
not affect the TAT level (fig.3) promotes the initial 
rate of enzyme induction by DBcAMP and the 
activity reaches a maximum 3 hr after injection of 
drugs as is the case of control animals without corti- 
sone. Given cortisone at the time of activity peak 
(3 hr), the rate of the following spontaneous activity 
decline is significantly prevented. However, cortisone 
has no effect on the rate of activity decay caused by 
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Fig.4. Time course of the effect of cortisone acetate on the 
DBcAMP-mediated induction of TAT. Adrenalectomized 
rats were injected with DBcAMP (3 mg/lOO g), cortisone ace- 
tate (0.2 mg) or cycloheximide (0.3 mg) alone and in combi- 
nation as follows: DBcAMP at zero time alone (o-o), 
DBcAMP and cortisone acetate at zero time (o---o), DBcAMP 
at zero time and cortisone acetate 3 hr later (*---•), DBcAMP 
at zero time and cycloheximide at 1.5 hr without (X-X) and 
with cortisone acetate (X---X). Data are mean f SE. for 5 or 
6 rats. 
Table 1 
Effect of actinomycin D on the induction of tyrosine 
aminotransferase by DBcAMP in the presence and absence 
of cortisone acetate 
Administration Actinomycin D Tyrosine amino- 
transferase 
(units/g liver) 
None _ 228.5 f 43.5 
DBcAMP 325.0 + 40.7 
+ 212.0 * 20.6 
DBcAMP _ 432.0 t 58.0 
+ Cortisone acetate + 179.5 * 22.0 
Adrenalectomized rats received actinomycin D (100 pg/lOO g) 
30 min prior tp DBcAMP (3 mg/lOO g) or DBcAMP plus corti- 
sone acetate (0.2 mg/lOO g) and the enzyme was assayed 3 hr 
after the inducers. Data are mean r S.E. for 5 rats. 
cycloheximide injection at a rapidly inducing phase 
(1.5 hr). 
Actinomycin D at a dose of 100 pg/lOO g com- 
pletely depresses the effect of DBcAMP both in the 
presence and absence of cortisone acetate (table 1). 
The result indicates that RNA synthesis is involved 
both in the cortisone-dependent and -independent 
induction of TAT by DBcAMP. 
4. Discussion 
The impaired response of TAT to DBcAMP (or 
glucagon) in adrenalectomized rats can be restored by 
injecting a low dose of cortisone acetate, implicating 
a physiological role of glucocorticoids in the cyclic 
AMP-mediated induction of the enzyme. Since the 
reduced.inducibility in adrenalectomized rats, about 
40% of that in intact rats, persists for at least 8 days 
after operation, the possibility can be excluded that 
this 40% fraction of the enzyme induction is due to 
the remaining m-RNA or other factors required for 
TAT translation, that have been produced in the liver 
in response to endogenous glucocorticoids prior to 
adrenalectomy. Thus two actinomycin D-sensitive 
sites, glucocorticoid-dependent and - independent 
sites, are likely to be involved in the TAT induction 
by cyclic AMP. As the effective doses of DBcAMP 
do not differ from each other among the animals with 
and without glucocorticoids (fig.2) it seems probable 
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that cortisone acetate increases the amount of an 
unknown key factor which degrades rapidly but is 
required in common for the enzyme induction by 
cyclic AMP both in the presence and absence of gluco- 
corticoids. In the later case this factor might be regu- 
lated by substances other than glucocorticoids. Where- 
as independent sites in target cells are suggested for 
the action of glucocorticoids and cyclic AMP [ 141, 
there have been evidences for a synergistic effect 
between these hormones on TAT induction [2-41. It 
has been evidenced from in vivo and in vitro experi- 
ments that glucocorticoids do not facilitate the uptake 
of cyclic AMP by liver cells [4,5,15]. Recently Krone 
et al. [5] described a rapid decline in the induced 
level of TAT by a repeated injection of DBcAMP to 
basal one in adrenalectomized rats, which is prevented 
by hydrocortisone, whereas no such a decline was 
observed by ourselves (data not shown) and by Wicks 
et al. [2] in rat liver under the similar conditions and 
by Butcher et al. [4] in H-35 hepatoma cell culture. 
In all these previous works glucocorticoids were 
applied in such an amount, that it alone can induce 
the enzyme markedly. In the present work we found 
a ‘potentiating’ effect of cortisone on the cyclic 
AMP-mediated induction of the enzyme by adminis- 
trating a low dose of the glucocorticoid, which alone 
does not induce the enzyme. It seems likely that the 
previously observed synergistic effect is, in part at 
least, a reflex of this potentiating effect. Present 
result using cycloheximide as an inhibitor of TAT 
biosynthesis implicates that the effect of a small dose 
of cortisone acetate is not due to the stabilization of 
enzyme but to the stimulating action on the de novo 
TAT synthesis. The question, however, is to be solved 
directly in more elaborated experimental systems. 
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